<p>Curcumin, as a natural polyphenolic compound, exhibits multitargeting properties, low cytotoxicity, and significant synergistic antitumor effects. However, its clinical application is limited by several major factors, including low bioavailability, poor chemical stability, and limited clinical translation potential. This study has successfully developed a glycyrrhizic acid-based amorphous networked nanomaterial co-encapsulating curcumin and IR-813 (Cur-Gly-IR-813), effectively overcoming the limitations of curcumin such as poor water solubility, low bioavailability, and inadequate chemical stability. Optical characterization confirmed that Cur-Gly-IR-813 exhibits exceptional UV absorption photostability and favorable fluorescence properties. TEM analysis indicated that the composite material has a unique amorphous network structure, which provides a structural basis for its potential high drug loading capacity. In vitro drug release studies demonstrated that the nanocomposite exhibits favorable pH-responsive release behavior under weakly acidic conditions. Zeta potential and particle Size analysis indicate that Cur-Gly-IR-813 possesses a high surface negative charge and a small hydrodynamic diameter. These characteristics contribute to colloidal stability maintenance and facilitate its selective accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. CCK-8 cytotoxicity assays demonstrated that Cur-Gly-IR-813 exhibits significant and concentration-dependent inhibitory effects on the proliferation of multiple human tumor cell lines in vitro. In summary, the multifunctional nanocomposite Cur-Gly-IR-813 successfully developed in this study demonstrates promising application potential in the fields of tumor-targeted therapy.</p> Graphical Abstract <p></p>